cabazitaxel + prednisolone

Cabazitaxel + prednisolone is a **combination drug regimen** consisting of cabazitaxel, a second-generation taxane, and prednisolone, a glucocorticoid corticosteroid. This combination is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel. Cabazitaxel inhibits cell division by binding to and stabilizing tubulin, preventing microtubule disassembly and thus blocking mitosis. Prednisolone, serving as an alternative to prednisone, acts as an anti-inflammatory and immunosuppressant agent, and is used as supportive care to manage cancer-related symptoms and reduce certain toxicities associated with chemotherapy. The combination is approved based on randomized controlled trials demonstrating improved overall survival compared to alternative therapies. Both drugs are administered concurrently, with cabazitaxel given intravenously once every 3 weeks and prednisolone (or prednisone) administered daily orally during each cycle.